Dr. Blachly is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
1st Floor
Columbus, OH 43210Fax+1 614-293-6050
Education & Training
- Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014
- University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2007 - 2011
- University of Arkansas For Medical Sciences College of MedicineClass of 2007
Certifications & Licensure
- OH State Medical License 2011 - 2025
- AR State Medical License 2010 - 2023
Clinical Trials
- Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement Start of enrollment: 2019 Apr 10
Publications & Presentations
PubMed
- 1 citationsMultiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.Andrew Stiff, Maarten Fornerod, Bailee N Kain, Deedra Nicolet, Benjamin J Kelly
Nature Genetics. 2024-11-01 - A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies.Pinkal Desai, Sagar Lonial, Amanda Cashen, Manali Kamdar, Ian Flinn
Clinical Cancer Research. 2024-11-01 - White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia age...Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, Christopher J Walker, James S Blachly
American Journal of Hematology. 2024-11-01
Journal Articles
- NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor OutcomeEunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature
Abstracts/Posters
- The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic LeukemiaJames S. Blachly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Rapid Molecular Diagnostics for Acute Myeloid Leukemia Using Single-Molecule SequencingJames S. Blachly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Follo...James S. Blachly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clinical and Molecular Characteristics of Acute Myeloid Leukemia (AML) Patients with TP53 Mutations and TP73 Mutations2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Editorial Roundup: PennsylvaniaAugust 21st, 2021
- NCCN Annual Conference Sheds Light on Treatment Disparities, Significance of the Doctor-Patient Relationship, Supportive Care Issues, and the Latest Guidelines UpdatesMarch 29th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: